AC Immune S.A.
ACIU · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $244 | $356 | $158 | $338 |
| - Cash | $36 | $78 | $32 | $82 |
| + Debt | $5 | $3 | $3 | $3 |
| Enterprise Value | $213 | $281 | $129 | $259 |
| Revenue | $27 | $15 | $4 | $0 |
| % Growth | 84.5% | 276.1% | – | – |
| Gross Profit | -$35 | -$40 | $4 | $0 |
| % Margin | -129.1% | -268.9% | 100% | – |
| EBITDA | -$49 | -$52 | -$68 | -$70 |
| % Margin | -178% | -350.2% | -1,728.7% | – |
| Net Income | -$51 | -$54 | -$71 | -$73 |
| % Margin | -186.4% | -366.4% | -1,798% | – |
| EPS Diluted | -0.51 | -0.64 | -0.85 | -0.97 |
| % Growth | 20.3% | 24.7% | 12.4% | – |
| Operating Cash Flow | $66 | -$60 | -$74 | -$66 |
| Capital Expenditures | -$1 | -$1 | -$1 | -$3 |
| Free Cash Flow | $65 | -$61 | -$75 | -$68 |